Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature

Dineen, Michael; Hansen, Elizabeth; Guancial, Elizabeth A.; Sievert, Lynn; Sahasrabudhe, Deepak M.

doi:10.1177/1078155217701294

Cited by 12 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few cases of abiraterone-induced rhabdomyolysis have been described since 2011. 9–13 Interestingly, abiraterone was associated to rosuvastatin in nearly all the cases previously reported. 9,10,12…”

Section: Discussionmentioning

confidence: 97%

“…[3][4][5][6]8 Few cases of abiraterone-induced rhabdomyolysis have been described since 2011. [9][10][11][12][13] Interestingly, abiraterone was associated to rosuvastatin in nearly all the cases previously reported. 9,10,12 Our patient was 74 years old, had chronic kidney disease and had been treated with high doses of rosuvastatin for a few years, all three factors being associated with statin muscular toxicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature

Ould-Nana

Cillis

Gizzi

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Abiraterone has been rarely associated with severe rhabdomyolysis, but the mechanism of muscle toxicity is unknown. Case report We hereby present a case of severe rhabdomyolysis resulting in acute on chronic kidney injury following abiraterone initiation in a patient previously under rosuvastatin. Management and outcome Rhabdomyolysis was resolutive after rosuvastatin and abiraterone discontinuation, and kidney function recovered. There was no recurrence of muscle toxicity after re-initiation of abiraterone alone. Discussion Abiraterone selectively inhibits CYP17 as well as the hepatic transporter OATP1B1. OATP1B1 is an efflux transporter, whose function is to extract several drugs from the portal blood, allowing them to undergo hepatic metabolism. We hypothesize that abiraterone-induced inhibition of plasmatic uptake of rosuvastatin by OATP1B1 increased plasmatic concentration of rosuvastatin, leading to toxicity on muscle cells. We therefore suggest that the association between rosuvastatin and abiraterone should be avoided.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature

Ould-Nana

Cillis

Gizzi

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Elevated CK is the most sensitive measure for diagnosing rhabdomyolysis [ 9 ]. CK concentrations usually peak within the first 24 h of muscle injury [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

A case of rhabdomyolysis after kidney transplantation successfully managed with intensive continuous dialysis

Shahbazov

Fox

Alejo

et al. 2018

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Rhabdomyolysis is characterized by muscle cell death which can result in acute kidney injury from pigment nephropathy. We present a patient who developed rhabdomyolysis immediately after deceased donor kidney transplantation surgery and was managed with continuous renal replacement therapy that resulted in successful salvage of the kidney allograft. Patients who develop acute kidney failure requiring renal replacement therapy generally have a poor prognosis. It is worth noting that while continuous veno-venous hemofiltration (CVVHF) offers greater volume support and continuous clearance compared to hemodialysis (HD), recent studies have demonstrated no clinically significant improvement in clinical outcome between the two. Perhaps CVVHF is a better modality compared to HD in this setting to prevent further insult from pigment nephropathy to an allograft. A combination of early diagnosis and intensive continuous renal replacement therapy can be used for allograft salvage in a patient with rhabdomyolysis in the immediate post-kidney transplant period.

show abstract

“…Effets indésirables inattendusTrois cas d'insuffisance rénale aiguë isolée sont rapportés dans la BNPV, cet EI étant identifié comme signal dans la DAS. Dans la littérature, hormis des cas d'IRA survenant dans un contexte de rhabdomyolyse[37][38][39], nous n'avons pas identifié d'autre cas d'IRA sous abiratérone. Ce signal mérite de plus amples investigations.Les 3 cas d'AVC ischémiques rapportés dans la BNPV sont aussi identifiés comme signal dans la DAS.…”

unclassified

Profils d’effets indésirables sous abiratérone et enzalutamide : analyse descriptive des données de la base nationale de pharmacovigilance

et al. 2021

View full text Add to dashboard Cite

show abstract

Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature

Cited by 12 publications

References 10 publications

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature

A case of rhabdomyolysis after kidney transplantation successfully managed with intensive continuous dialysis

Profils d’effets indésirables sous abiratérone et enzalutamide : analyse descriptive des données de la base nationale de pharmacovigilance

Contact Info

Product

Resources

About